Fytili Christina I, Passadakis Ploumis S, Progia Euaggelia G, Kambouromiti Georgia L, Panopoulou Maria I, Sombolos Kostas I, Vargemezis Vassilis A
Biochemical Department, G.H.N. Papanikolaou Thessaloniki, Greece.
Ren Fail. 2002 Sep;24(5):631-8. doi: 10.1081/jdi-120013967.
Except for the disorders in lipoprotein metabolism several other factors have been involved in the development of atherosclerotic changes in ESRD patients, including arterial hypertension. Serum lipid profile (total cholesterol (TC), triglycerides (TG), apolipoproteins (AI,AII,B,E) and Lp(a)) was evaluated in 109 ESRD dialyzed patients, 46 in HD and 63 in CAPD and 45 hyperlipidemic patients without renal failure (HL-group). According to the presence of arterial hypertension the dialyzed patients were divided in two groups: group A of 42 hypertensive patients, (mean age 62.3 +/- 15.5 years), which were satisfactorily controlled with anti-hypertensive medication, and group B of 67 non-hypertensive patients, (mean age 66.6 +/- 11.9 years). Lp(a) levels were statistically significantly higher than HL group in both HD (p = 0.001) and PD (p < 0.05) patients. Besides, by dividing HD and PD group in hypertensive and non-hypertensive patients, Lp(a) levels were statistically significantly higher in hypertensive patients, while such a difference was not observed among non-renal failure patients. These results indicate that arterial hypertension may play an important role in Lp(a) serum titles, in ESRD patients undergoing either HD or PD.
除了脂蛋白代谢紊乱外,其他一些因素也与终末期肾病(ESRD)患者动脉粥样硬化病变的发展有关,包括动脉高血压。对109例接受透析的ESRD患者、46例接受血液透析(HD)的患者、63例接受持续性非卧床腹膜透析(CAPD)的患者以及45例无肾衰竭的高脂血症患者(HL组)的血脂谱(总胆固醇(TC)、甘油三酯(TG)、载脂蛋白(AI、AII、B、E)和脂蛋白(a)[Lp(a)])进行了评估。根据是否存在动脉高血压,将透析患者分为两组:A组为42例高血压患者(平均年龄62.3±15.5岁),他们通过抗高血压药物得到了满意控制;B组为67例非高血压患者(平均年龄66.6±11.9岁)。HD患者(p = 0.001)和腹膜透析(PD)患者(p < 0.05)的Lp(a)水平均显著高于HL组。此外,将HD组和PD组再分为高血压患者和非高血压患者后,高血压患者的Lp(a)水平在统计学上显著更高,而在无肾衰竭患者中未观察到这种差异。这些结果表明,动脉高血压可能在接受HD或PD治疗的ESRD患者的血清Lp(a)水平中起重要作用。